nodes	percent_of_prediction	percent_of_DWPC	metapath
Atomoxetine—CYP2C19—prostate cancer	0.184	0.611	CbGaD
Atomoxetine—CYP3A4—prostate cancer	0.117	0.389	CbGaD
Atomoxetine—CYP2C19—Nilutamide—prostate cancer	0.0399	0.106	CbGbCtD
Atomoxetine—CYP2C19—Bicalutamide—prostate cancer	0.0399	0.106	CbGbCtD
Atomoxetine—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0367	0.0976	CbGbCtD
Atomoxetine—CYP2C19—Flutamide—prostate cancer	0.0331	0.0879	CbGbCtD
Atomoxetine—CYP2D6—Bicalutamide—prostate cancer	0.0303	0.0806	CbGbCtD
Atomoxetine—CYP2D6—Abiraterone—prostate cancer	0.0251	0.0668	CbGbCtD
Atomoxetine—CYP3A4—Bicalutamide—prostate cancer	0.0193	0.0513	CbGbCtD
Atomoxetine—CYP3A4—Estramustine—prostate cancer	0.0179	0.0477	CbGbCtD
Atomoxetine—CYP3A4—Abiraterone—prostate cancer	0.016	0.0425	CbGbCtD
Atomoxetine—CYP3A4—Flutamide—prostate cancer	0.016	0.0425	CbGbCtD
Atomoxetine—CYP2C19—Estradiol—prostate cancer	0.0137	0.0365	CbGbCtD
Atomoxetine—CYP3A4—Cabazitaxel—prostate cancer	0.0118	0.0314	CbGbCtD
Atomoxetine—CYP2C19—Prednisone—prostate cancer	0.0118	0.0314	CbGbCtD
Atomoxetine—CYP3A4—Estrone—prostate cancer	0.0116	0.0307	CbGbCtD
Atomoxetine—CYP3A4—Ethinyl Estradiol—prostate cancer	0.0103	0.0274	CbGbCtD
Atomoxetine—CYP3A4—Conjugated Estrogens—prostate cancer	0.00756	0.0201	CbGbCtD
Atomoxetine—CYP3A4—Mitoxantrone—prostate cancer	0.00687	0.0183	CbGbCtD
Atomoxetine—CYP3A4—Estradiol—prostate cancer	0.00664	0.0176	CbGbCtD
Atomoxetine—CYP3A4—Prednisone—prostate cancer	0.00571	0.0152	CbGbCtD
Atomoxetine—CYP2D6—Doxorubicin—prostate cancer	0.00465	0.0124	CbGbCtD
Atomoxetine—CYP3A4—Etoposide—prostate cancer	0.00433	0.0115	CbGbCtD
Atomoxetine—CYP3A4—Docetaxel—prostate cancer	0.00396	0.0105	CbGbCtD
Atomoxetine—CYP3A4—Doxorubicin—prostate cancer	0.00296	0.00786	CbGbCtD
Atomoxetine—NPY1R—prostate gland—prostate cancer	0.00229	0.144	CbGeAlD
Atomoxetine—CYP2C19—urine—prostate cancer	0.00204	0.128	CbGeAlD
Atomoxetine—NPY1R—seminal vesicle—prostate cancer	0.00194	0.122	CbGeAlD
Atomoxetine—NPY1R—renal system—prostate cancer	0.00156	0.0981	CbGeAlD
Atomoxetine—HTR2A—urine—prostate cancer	0.0013	0.0818	CbGeAlD
Atomoxetine—CYP3A4—urine—prostate cancer	0.0012	0.0757	CbGeAlD
Atomoxetine—CYP2D6—urine—prostate cancer	0.00118	0.0745	CbGeAlD
Atomoxetine—NPY1R—testis—prostate cancer	0.00101	0.0634	CbGeAlD
Atomoxetine—Cyclizine—SULT1E1—prostate cancer	0.000812	0.158	CrCbGaD
Atomoxetine—NPY1R—lymph node—prostate cancer	0.000731	0.046	CbGeAlD
Atomoxetine—SLC6A3—testis—prostate cancer	0.000424	0.0267	CbGeAlD
Atomoxetine—HTR2A—epithelium—prostate cancer	0.000343	0.0216	CbGeAlD
Atomoxetine—SLC6A2—testis—prostate cancer	0.000342	0.0215	CbGeAlD
Atomoxetine—HTR2A—renal system—prostate cancer	0.000318	0.02	CbGeAlD
Atomoxetine—Pseudoephedrine—IL2—prostate cancer	0.000306	0.0594	CrCbGaD
Atomoxetine—CYP3A4—renal system—prostate cancer	0.000295	0.0185	CbGeAlD
Atomoxetine—CYP2D6—renal system—prostate cancer	0.00029	0.0182	CbGeAlD
Atomoxetine—SLC6A2—lymph node—prostate cancer	0.000248	0.0156	CbGeAlD
Atomoxetine—Ephedrine—ACHE—prostate cancer	0.000239	0.0464	CrCbGaD
Atomoxetine—HTR2A—testis—prostate cancer	0.000206	0.0129	CbGeAlD
Atomoxetine—CYP2D6—testis—prostate cancer	0.000187	0.0118	CbGeAlD
Atomoxetine—Warfarin—CYP2C18—prostate cancer	0.000184	0.0358	CrCbGaD
Atomoxetine—Phenoxybenzamine—SLC22A3—prostate cancer	0.000142	0.0277	CrCbGaD
Atomoxetine—Ketoprofen—CXCL8—prostate cancer	0.000136	0.0264	CrCbGaD
Atomoxetine—Fluoxetine—CYP3A5—prostate cancer	0.000133	0.0259	CrCbGaD
Atomoxetine—Ephedrine—ADRB2—prostate cancer	0.000121	0.0234	CrCbGaD
Atomoxetine—Desipramine—SLC22A3—prostate cancer	0.000106	0.0207	CrCbGaD
Atomoxetine—Diphenhydramine—CYP2C18—prostate cancer	0.000105	0.0204	CrCbGaD
Atomoxetine—Phenoxybenzamine—SLC22A1—prostate cancer	0.000102	0.0198	CrCbGaD
Atomoxetine—Methadone—CYP2C18—prostate cancer	0.000101	0.0197	CrCbGaD
Atomoxetine—Modafinil—CYP3A5—prostate cancer	9.94e-05	0.0193	CrCbGaD
Atomoxetine—Tolterodine—CYP2C19—prostate cancer	9.5e-05	0.0185	CrCbGaD
Atomoxetine—Desipramine—CYP2C18—prostate cancer	9.34e-05	0.0181	CrCbGaD
Atomoxetine—Reboxetine—CYP3A4—prostate cancer	9.19e-05	0.0179	CrCbGaD
Atomoxetine—Benzatropine—CYP2C19—prostate cancer	9.14e-05	0.0178	CrCbGaD
Atomoxetine—Pseudoephedrine—ADRB2—prostate cancer	9.14e-05	0.0178	CrCbGaD
Atomoxetine—Fluoxetine—CYP2C19—prostate cancer	9.06e-05	0.0176	CrCbGaD
Atomoxetine—Diphenhydramine—SLC22A1—prostate cancer	8.56e-05	0.0166	CrCbGaD
Atomoxetine—Warfarin—CYP2C19—prostate cancer	8.26e-05	0.0161	CrCbGaD
Atomoxetine—Warfarin—CYP1A1—prostate cancer	8.23e-05	0.016	CrCbGaD
Atomoxetine—Propranolol—CYP3A5—prostate cancer	8.13e-05	0.0158	CrCbGaD
Atomoxetine—Desipramine—SLC22A1—prostate cancer	7.62e-05	0.0148	CrCbGaD
Atomoxetine—Nortriptyline—CYP3A5—prostate cancer	7.47e-05	0.0145	CrCbGaD
Atomoxetine—Modafinil—CYP2C19—prostate cancer	6.77e-05	0.0132	CrCbGaD
Atomoxetine—Fenoprofen—PTGS2—prostate cancer	6.73e-05	0.0131	CrCbGaD
Atomoxetine—Methadone—CYP3A5—prostate cancer	6.67e-05	0.013	CrCbGaD
Atomoxetine—Phenoxybenzamine—ADRB2—prostate cancer	6.52e-05	0.0127	CrCbGaD
Atomoxetine—Propranolol—ADRB2—prostate cancer	6.42e-05	0.0125	CrCbGaD
Atomoxetine—Methadone—CYP19A1—prostate cancer	6.15e-05	0.0119	CrCbGaD
Atomoxetine—Infection—Docetaxel—prostate cancer	6.07e-05	0.000306	CcSEcCtD
Atomoxetine—Weight decreased—Doxorubicin—prostate cancer	6.07e-05	0.000306	CcSEcCtD
Atomoxetine—Sinusitis—Epirubicin—prostate cancer	6.06e-05	0.000306	CcSEcCtD
Atomoxetine—Feeling abnormal—Etoposide—prostate cancer	6.06e-05	0.000305	CcSEcCtD
Atomoxetine—Diarrhoea—Mitoxantrone—prostate cancer	6.05e-05	0.000305	CcSEcCtD
Atomoxetine—Tolterodine—CYP3A4—prostate cancer	6.04e-05	0.0117	CrCbGaD
Atomoxetine—Dry mouth—Capecitabine—prostate cancer	6.03e-05	0.000304	CcSEcCtD
Atomoxetine—Vomiting—Estradiol—prostate cancer	6.03e-05	0.000304	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Etoposide—prostate cancer	6.01e-05	0.000303	CcSEcCtD
Atomoxetine—Shock—Docetaxel—prostate cancer	6.01e-05	0.000303	CcSEcCtD
Atomoxetine—Nervous system disorder—Docetaxel—prostate cancer	5.99e-05	0.000302	CcSEcCtD
Atomoxetine—Rash—Estradiol—prostate cancer	5.98e-05	0.000302	CcSEcCtD
Atomoxetine—Infestation NOS—Doxorubicin—prostate cancer	5.98e-05	0.000301	CcSEcCtD
Atomoxetine—Infestation—Doxorubicin—prostate cancer	5.98e-05	0.000301	CcSEcCtD
Atomoxetine—Dermatitis—Estradiol—prostate cancer	5.98e-05	0.000301	CcSEcCtD
Atomoxetine—Tachycardia—Docetaxel—prostate cancer	5.96e-05	0.000301	CcSEcCtD
Atomoxetine—Desipramine—CYP2A6—prostate cancer	5.96e-05	0.0116	CrCbGaD
Atomoxetine—Headache—Estradiol—prostate cancer	5.94e-05	0.0003	CcSEcCtD
Atomoxetine—Skin disorder—Docetaxel—prostate cancer	5.93e-05	0.000299	CcSEcCtD
Atomoxetine—Agitation—Prednisone—prostate cancer	5.93e-05	0.000299	CcSEcCtD
Atomoxetine—Phenprocoumon—CYP3A4—prostate cancer	5.92e-05	0.0115	CrCbGaD
Atomoxetine—Infection—Capecitabine—prostate cancer	5.88e-05	0.000296	CcSEcCtD
Atomoxetine—Urticaria—Etoposide—prostate cancer	5.84e-05	0.000294	CcSEcCtD
Atomoxetine—Anorexia—Docetaxel—prostate cancer	5.82e-05	0.000294	CcSEcCtD
Atomoxetine—Shock—Capecitabine—prostate cancer	5.82e-05	0.000293	CcSEcCtD
Atomoxetine—Body temperature increased—Etoposide—prostate cancer	5.81e-05	0.000293	CcSEcCtD
Atomoxetine—Abdominal pain—Etoposide—prostate cancer	5.81e-05	0.000293	CcSEcCtD
Atomoxetine—Conjunctivitis—Doxorubicin—prostate cancer	5.81e-05	0.000293	CcSEcCtD
Atomoxetine—Nervous system disorder—Capecitabine—prostate cancer	5.8e-05	0.000292	CcSEcCtD
Atomoxetine—Vertigo—Prednisone—prostate cancer	5.8e-05	0.000292	CcSEcCtD
Atomoxetine—Syncope—Prednisone—prostate cancer	5.79e-05	0.000292	CcSEcCtD
Atomoxetine—Tachycardia—Capecitabine—prostate cancer	5.77e-05	0.000291	CcSEcCtD
Atomoxetine—Hypoaesthesia—Epirubicin—prostate cancer	5.77e-05	0.000291	CcSEcCtD
Atomoxetine—Fluoxetine—CYP3A4—prostate cancer	5.76e-05	0.0112	CrCbGaD
Atomoxetine—Skin disorder—Capecitabine—prostate cancer	5.75e-05	0.00029	CcSEcCtD
Atomoxetine—Urinary tract disorder—Epirubicin—prostate cancer	5.73e-05	0.000289	CcSEcCtD
Atomoxetine—Hyperhidrosis—Capecitabine—prostate cancer	5.72e-05	0.000288	CcSEcCtD
Atomoxetine—Urethral disorder—Epirubicin—prostate cancer	5.69e-05	0.000287	CcSEcCtD
Atomoxetine—Loss of consciousness—Prednisone—prostate cancer	5.67e-05	0.000286	CcSEcCtD
Atomoxetine—Anorexia—Capecitabine—prostate cancer	5.64e-05	0.000284	CcSEcCtD
Atomoxetine—Nausea—Estradiol—prostate cancer	5.63e-05	0.000284	CcSEcCtD
Atomoxetine—Vomiting—Mitoxantrone—prostate cancer	5.62e-05	0.000283	CcSEcCtD
Atomoxetine—Sinusitis—Doxorubicin—prostate cancer	5.61e-05	0.000283	CcSEcCtD
Atomoxetine—Convulsion—Prednisone—prostate cancer	5.59e-05	0.000282	CcSEcCtD
Atomoxetine—Rash—Mitoxantrone—prostate cancer	5.57e-05	0.000281	CcSEcCtD
Atomoxetine—Dermatitis—Mitoxantrone—prostate cancer	5.57e-05	0.000281	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Docetaxel—prostate cancer	5.57e-05	0.000281	CcSEcCtD
Atomoxetine—Headache—Mitoxantrone—prostate cancer	5.54e-05	0.000279	CcSEcCtD
Atomoxetine—Propranolol—CYP2C19—prostate cancer	5.53e-05	0.0107	CrCbGaD
Atomoxetine—Insomnia—Docetaxel—prostate cancer	5.53e-05	0.000279	CcSEcCtD
Atomoxetine—Propranolol—CYP1A1—prostate cancer	5.51e-05	0.0107	CrCbGaD
Atomoxetine—Arthralgia—Prednisone—prostate cancer	5.5e-05	0.000277	CcSEcCtD
Atomoxetine—Myalgia—Prednisone—prostate cancer	5.5e-05	0.000277	CcSEcCtD
Atomoxetine—Paraesthesia—Docetaxel—prostate cancer	5.49e-05	0.000277	CcSEcCtD
Atomoxetine—Anxiety—Prednisone—prostate cancer	5.48e-05	0.000276	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	5.46e-05	0.000275	CcSEcCtD
Atomoxetine—Somnolence—Docetaxel—prostate cancer	5.43e-05	0.000274	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Capecitabine—prostate cancer	5.39e-05	0.000272	CcSEcCtD
Atomoxetine—Flushing—Epirubicin—prostate cancer	5.38e-05	0.000271	CcSEcCtD
Atomoxetine—Cardiac disorder—Epirubicin—prostate cancer	5.38e-05	0.000271	CcSEcCtD
Atomoxetine—Dyspepsia—Docetaxel—prostate cancer	5.38e-05	0.000271	CcSEcCtD
Atomoxetine—Insomnia—Capecitabine—prostate cancer	5.35e-05	0.00027	CcSEcCtD
Atomoxetine—Hypoaesthesia—Doxorubicin—prostate cancer	5.34e-05	0.000269	CcSEcCtD
Atomoxetine—Paraesthesia—Capecitabine—prostate cancer	5.31e-05	0.000268	CcSEcCtD
Atomoxetine—Decreased appetite—Docetaxel—prostate cancer	5.31e-05	0.000268	CcSEcCtD
Atomoxetine—Urinary tract disorder—Doxorubicin—prostate cancer	5.3e-05	0.000267	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Docetaxel—prostate cancer	5.27e-05	0.000266	CcSEcCtD
Atomoxetine—Asthenia—Etoposide—prostate cancer	5.27e-05	0.000266	CcSEcCtD
Atomoxetine—Fatigue—Docetaxel—prostate cancer	5.27e-05	0.000266	CcSEcCtD
Atomoxetine—Angiopathy—Epirubicin—prostate cancer	5.26e-05	0.000265	CcSEcCtD
Atomoxetine—Urethral disorder—Doxorubicin—prostate cancer	5.26e-05	0.000265	CcSEcCtD
Atomoxetine—Warfarin—CYP3A4—prostate cancer	5.26e-05	0.0102	CrCbGaD
Atomoxetine—Nausea—Mitoxantrone—prostate cancer	5.25e-05	0.000265	CcSEcCtD
Atomoxetine—Infection—Prednisone—prostate cancer	5.23e-05	0.000264	CcSEcCtD
Atomoxetine—Mediastinal disorder—Epirubicin—prostate cancer	5.23e-05	0.000264	CcSEcCtD
Atomoxetine—Constipation—Docetaxel—prostate cancer	5.22e-05	0.000263	CcSEcCtD
Atomoxetine—Pain—Docetaxel—prostate cancer	5.22e-05	0.000263	CcSEcCtD
Atomoxetine—Dyspepsia—Capecitabine—prostate cancer	5.21e-05	0.000262	CcSEcCtD
Atomoxetine—Chills—Epirubicin—prostate cancer	5.2e-05	0.000262	CcSEcCtD
Atomoxetine—Pruritus—Etoposide—prostate cancer	5.2e-05	0.000262	CcSEcCtD
Atomoxetine—Shock—Prednisone—prostate cancer	5.18e-05	0.000261	CcSEcCtD
Atomoxetine—Nervous system disorder—Prednisone—prostate cancer	5.17e-05	0.00026	CcSEcCtD
Atomoxetine—Tachycardia—Prednisone—prostate cancer	5.14e-05	0.000259	CcSEcCtD
Atomoxetine—Decreased appetite—Capecitabine—prostate cancer	5.14e-05	0.000259	CcSEcCtD
Atomoxetine—Propafenone—CYP3A4—prostate cancer	5.14e-05	0.00998	CrCbGaD
Atomoxetine—Nortriptyline—CYP2E1—prostate cancer	5.14e-05	0.00998	CrCbGaD
Atomoxetine—Skin disorder—Prednisone—prostate cancer	5.12e-05	0.000258	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Capecitabine—prostate cancer	5.11e-05	0.000257	CcSEcCtD
Atomoxetine—Fatigue—Capecitabine—prostate cancer	5.1e-05	0.000257	CcSEcCtD
Atomoxetine—Hyperhidrosis—Prednisone—prostate cancer	5.09e-05	0.000257	CcSEcCtD
Atomoxetine—Nortriptyline—CYP2C19—prostate cancer	5.09e-05	0.00988	CrCbGaD
Atomoxetine—Mental disorder—Epirubicin—prostate cancer	5.08e-05	0.000256	CcSEcCtD
Atomoxetine—Constipation—Capecitabine—prostate cancer	5.06e-05	0.000255	CcSEcCtD
Atomoxetine—Pain—Capecitabine—prostate cancer	5.06e-05	0.000255	CcSEcCtD
Atomoxetine—Malnutrition—Epirubicin—prostate cancer	5.05e-05	0.000255	CcSEcCtD
Atomoxetine—Feeling abnormal—Docetaxel—prostate cancer	5.03e-05	0.000254	CcSEcCtD
Atomoxetine—Diarrhoea—Etoposide—prostate cancer	5.03e-05	0.000254	CcSEcCtD
Atomoxetine—Anorexia—Prednisone—prostate cancer	5.02e-05	0.000253	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Docetaxel—prostate cancer	5e-05	0.000252	CcSEcCtD
Atomoxetine—Flushing—Doxorubicin—prostate cancer	4.98e-05	0.000251	CcSEcCtD
Atomoxetine—Cardiac disorder—Doxorubicin—prostate cancer	4.98e-05	0.000251	CcSEcCtD
Atomoxetine—Flatulence—Epirubicin—prostate cancer	4.98e-05	0.000251	CcSEcCtD
Atomoxetine—Tension—Epirubicin—prostate cancer	4.95e-05	0.00025	CcSEcCtD
Atomoxetine—Dysgeusia—Epirubicin—prostate cancer	4.94e-05	0.000249	CcSEcCtD
Atomoxetine—Nervousness—Epirubicin—prostate cancer	4.9e-05	0.000247	CcSEcCtD
Atomoxetine—Back pain—Epirubicin—prostate cancer	4.88e-05	0.000246	CcSEcCtD
Atomoxetine—Feeling abnormal—Capecitabine—prostate cancer	4.87e-05	0.000246	CcSEcCtD
Atomoxetine—Angiopathy—Doxorubicin—prostate cancer	4.87e-05	0.000245	CcSEcCtD
Atomoxetine—Desipramine—ADRB2—prostate cancer	4.86e-05	0.00945	CrCbGaD
Atomoxetine—Dizziness—Etoposide—prostate cancer	4.86e-05	0.000245	CcSEcCtD
Atomoxetine—Muscle spasms—Epirubicin—prostate cancer	4.85e-05	0.000245	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Capecitabine—prostate cancer	4.84e-05	0.000244	CcSEcCtD
Atomoxetine—Mediastinal disorder—Doxorubicin—prostate cancer	4.84e-05	0.000244	CcSEcCtD
Atomoxetine—Body temperature increased—Docetaxel—prostate cancer	4.83e-05	0.000243	CcSEcCtD
Atomoxetine—Abdominal pain—Docetaxel—prostate cancer	4.83e-05	0.000243	CcSEcCtD
Atomoxetine—Chills—Doxorubicin—prostate cancer	4.82e-05	0.000243	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Prednisone—prostate cancer	4.8e-05	0.000242	CcSEcCtD
Atomoxetine—Insomnia—Prednisone—prostate cancer	4.77e-05	0.00024	CcSEcCtD
Atomoxetine—Vision blurred—Epirubicin—prostate cancer	4.76e-05	0.00024	CcSEcCtD
Atomoxetine—Paraesthesia—Prednisone—prostate cancer	4.73e-05	0.000239	CcSEcCtD
Atomoxetine—Diphenhydramine—CYP2C19—prostate cancer	4.7e-05	0.00914	CrCbGaD
Atomoxetine—Mental disorder—Doxorubicin—prostate cancer	4.7e-05	0.000237	CcSEcCtD
Atomoxetine—Urticaria—Capecitabine—prostate cancer	4.7e-05	0.000237	CcSEcCtD
Atomoxetine—Body temperature increased—Capecitabine—prostate cancer	4.68e-05	0.000236	CcSEcCtD
Atomoxetine—Abdominal pain—Capecitabine—prostate cancer	4.68e-05	0.000236	CcSEcCtD
Atomoxetine—Vomiting—Etoposide—prostate cancer	4.67e-05	0.000236	CcSEcCtD
Atomoxetine—Malnutrition—Doxorubicin—prostate cancer	4.67e-05	0.000236	CcSEcCtD
Atomoxetine—Agitation—Epirubicin—prostate cancer	4.64e-05	0.000234	CcSEcCtD
Atomoxetine—Dyspepsia—Prednisone—prostate cancer	4.64e-05	0.000234	CcSEcCtD
Atomoxetine—Rash—Etoposide—prostate cancer	4.64e-05	0.000234	CcSEcCtD
Atomoxetine—Dermatitis—Etoposide—prostate cancer	4.63e-05	0.000233	CcSEcCtD
Atomoxetine—Headache—Etoposide—prostate cancer	4.61e-05	0.000232	CcSEcCtD
Atomoxetine—Flatulence—Doxorubicin—prostate cancer	4.6e-05	0.000232	CcSEcCtD
Atomoxetine—Tension—Doxorubicin—prostate cancer	4.58e-05	0.000231	CcSEcCtD
Atomoxetine—Decreased appetite—Prednisone—prostate cancer	4.58e-05	0.000231	CcSEcCtD
Atomoxetine—Dysgeusia—Doxorubicin—prostate cancer	4.58e-05	0.000231	CcSEcCtD
Atomoxetine—Fatigue—Prednisone—prostate cancer	4.54e-05	0.000229	CcSEcCtD
Atomoxetine—Methadone—CYP2C19—prostate cancer	4.54e-05	0.00882	CrCbGaD
Atomoxetine—Nervousness—Doxorubicin—prostate cancer	4.54e-05	0.000229	CcSEcCtD
Atomoxetine—Vertigo—Epirubicin—prostate cancer	4.54e-05	0.000229	CcSEcCtD
Atomoxetine—Syncope—Epirubicin—prostate cancer	4.53e-05	0.000228	CcSEcCtD
Atomoxetine—Back pain—Doxorubicin—prostate cancer	4.52e-05	0.000228	CcSEcCtD
Atomoxetine—Constipation—Prednisone—prostate cancer	4.51e-05	0.000227	CcSEcCtD
Atomoxetine—Muscle spasms—Doxorubicin—prostate cancer	4.49e-05	0.000226	CcSEcCtD
Atomoxetine—Orphenadrine—CYP2E1—prostate cancer	4.49e-05	0.00873	CrCbGaD
Atomoxetine—Palpitations—Epirubicin—prostate cancer	4.46e-05	0.000225	CcSEcCtD
Atomoxetine—Loss of consciousness—Epirubicin—prostate cancer	4.44e-05	0.000224	CcSEcCtD
Atomoxetine—Cough—Epirubicin—prostate cancer	4.41e-05	0.000222	CcSEcCtD
Atomoxetine—Vision blurred—Doxorubicin—prostate cancer	4.4e-05	0.000222	CcSEcCtD
Atomoxetine—Asthenia—Docetaxel—prostate cancer	4.38e-05	0.000221	CcSEcCtD
Atomoxetine—Convulsion—Epirubicin—prostate cancer	4.37e-05	0.000221	CcSEcCtD
Atomoxetine—Nausea—Etoposide—prostate cancer	4.37e-05	0.00022	CcSEcCtD
Atomoxetine—Feeling abnormal—Prednisone—prostate cancer	4.34e-05	0.000219	CcSEcCtD
Atomoxetine—Pruritus—Docetaxel—prostate cancer	4.32e-05	0.000218	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Prednisone—prostate cancer	4.31e-05	0.000217	CcSEcCtD
Atomoxetine—Modafinil—CYP3A4—prostate cancer	4.3e-05	0.00836	CrCbGaD
Atomoxetine—Arthralgia—Epirubicin—prostate cancer	4.3e-05	0.000217	CcSEcCtD
Atomoxetine—Myalgia—Epirubicin—prostate cancer	4.3e-05	0.000217	CcSEcCtD
Atomoxetine—Chest pain—Epirubicin—prostate cancer	4.3e-05	0.000217	CcSEcCtD
Atomoxetine—Agitation—Doxorubicin—prostate cancer	4.29e-05	0.000216	CcSEcCtD
Atomoxetine—Anxiety—Epirubicin—prostate cancer	4.28e-05	0.000216	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	4.27e-05	0.000215	CcSEcCtD
Atomoxetine—Asthenia—Capecitabine—prostate cancer	4.24e-05	0.000214	CcSEcCtD
Atomoxetine—Desipramine—CYP2E1—prostate cancer	4.23e-05	0.00822	CrCbGaD
Atomoxetine—Dry mouth—Epirubicin—prostate cancer	4.2e-05	0.000212	CcSEcCtD
Atomoxetine—Vertigo—Doxorubicin—prostate cancer	4.2e-05	0.000212	CcSEcCtD
Atomoxetine—Syncope—Doxorubicin—prostate cancer	4.19e-05	0.000211	CcSEcCtD
Atomoxetine—Desipramine—CYP2C19—prostate cancer	4.19e-05	0.00814	CrCbGaD
Atomoxetine—Urticaria—Prednisone—prostate cancer	4.19e-05	0.000211	CcSEcCtD
Atomoxetine—Pruritus—Capecitabine—prostate cancer	4.19e-05	0.000211	CcSEcCtD
Atomoxetine—Diarrhoea—Docetaxel—prostate cancer	4.18e-05	0.000211	CcSEcCtD
Atomoxetine—Body temperature increased—Prednisone—prostate cancer	4.17e-05	0.00021	CcSEcCtD
Atomoxetine—Abdominal pain—Prednisone—prostate cancer	4.17e-05	0.00021	CcSEcCtD
Atomoxetine—Palpitations—Doxorubicin—prostate cancer	4.13e-05	0.000208	CcSEcCtD
Atomoxetine—Loss of consciousness—Doxorubicin—prostate cancer	4.11e-05	0.000207	CcSEcCtD
Atomoxetine—Infection—Epirubicin—prostate cancer	4.09e-05	0.000206	CcSEcCtD
Atomoxetine—Cough—Doxorubicin—prostate cancer	4.08e-05	0.000206	CcSEcCtD
Atomoxetine—Shock—Epirubicin—prostate cancer	4.05e-05	0.000204	CcSEcCtD
Atomoxetine—Convulsion—Doxorubicin—prostate cancer	4.05e-05	0.000204	CcSEcCtD
Atomoxetine—Diarrhoea—Capecitabine—prostate cancer	4.05e-05	0.000204	CcSEcCtD
Atomoxetine—Nervous system disorder—Epirubicin—prostate cancer	4.04e-05	0.000204	CcSEcCtD
Atomoxetine—Dizziness—Docetaxel—prostate cancer	4.04e-05	0.000204	CcSEcCtD
Atomoxetine—Tachycardia—Epirubicin—prostate cancer	4.02e-05	0.000203	CcSEcCtD
Atomoxetine—Skin disorder—Epirubicin—prostate cancer	4e-05	0.000202	CcSEcCtD
Atomoxetine—Hyperhidrosis—Epirubicin—prostate cancer	3.98e-05	0.000201	CcSEcCtD
Atomoxetine—Myalgia—Doxorubicin—prostate cancer	3.98e-05	0.000201	CcSEcCtD
Atomoxetine—Chest pain—Doxorubicin—prostate cancer	3.98e-05	0.000201	CcSEcCtD
Atomoxetine—Arthralgia—Doxorubicin—prostate cancer	3.98e-05	0.000201	CcSEcCtD
Atomoxetine—Ketoprofen—PTGS2—prostate cancer	3.97e-05	0.00771	CrCbGaD
Atomoxetine—Anxiety—Doxorubicin—prostate cancer	3.96e-05	0.0002	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	3.95e-05	0.000199	CcSEcCtD
Atomoxetine—Anorexia—Epirubicin—prostate cancer	3.93e-05	0.000198	CcSEcCtD
Atomoxetine—Dizziness—Capecitabine—prostate cancer	3.91e-05	0.000197	CcSEcCtD
Atomoxetine—Dry mouth—Doxorubicin—prostate cancer	3.89e-05	0.000196	CcSEcCtD
Atomoxetine—Vomiting—Docetaxel—prostate cancer	3.88e-05	0.000196	CcSEcCtD
Atomoxetine—Rash—Docetaxel—prostate cancer	3.85e-05	0.000194	CcSEcCtD
Atomoxetine—Dermatitis—Docetaxel—prostate cancer	3.85e-05	0.000194	CcSEcCtD
Atomoxetine—Headache—Docetaxel—prostate cancer	3.83e-05	0.000193	CcSEcCtD
Atomoxetine—Infection—Doxorubicin—prostate cancer	3.79e-05	0.000191	CcSEcCtD
Atomoxetine—Asthenia—Prednisone—prostate cancer	3.78e-05	0.000191	CcSEcCtD
Atomoxetine—Vomiting—Capecitabine—prostate cancer	3.76e-05	0.00019	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Epirubicin—prostate cancer	3.75e-05	0.000189	CcSEcCtD
Atomoxetine—Shock—Doxorubicin—prostate cancer	3.75e-05	0.000189	CcSEcCtD
Atomoxetine—Nervous system disorder—Doxorubicin—prostate cancer	3.74e-05	0.000189	CcSEcCtD
Atomoxetine—Benzphetamine—CYP3A4—prostate cancer	3.73e-05	0.00725	CrCbGaD
Atomoxetine—Rash—Capecitabine—prostate cancer	3.73e-05	0.000188	CcSEcCtD
Atomoxetine—Pruritus—Prednisone—prostate cancer	3.73e-05	0.000188	CcSEcCtD
Atomoxetine—Insomnia—Epirubicin—prostate cancer	3.73e-05	0.000188	CcSEcCtD
Atomoxetine—Dermatitis—Capecitabine—prostate cancer	3.73e-05	0.000188	CcSEcCtD
Atomoxetine—Tachycardia—Doxorubicin—prostate cancer	3.72e-05	0.000188	CcSEcCtD
Atomoxetine—Headache—Capecitabine—prostate cancer	3.71e-05	0.000187	CcSEcCtD
Atomoxetine—Skin disorder—Doxorubicin—prostate cancer	3.7e-05	0.000187	CcSEcCtD
Atomoxetine—Paraesthesia—Epirubicin—prostate cancer	3.7e-05	0.000187	CcSEcCtD
Atomoxetine—Hyperhidrosis—Doxorubicin—prostate cancer	3.69e-05	0.000186	CcSEcCtD
Atomoxetine—Somnolence—Epirubicin—prostate cancer	3.66e-05	0.000185	CcSEcCtD
Atomoxetine—Anorexia—Doxorubicin—prostate cancer	3.63e-05	0.000183	CcSEcCtD
Atomoxetine—Nausea—Docetaxel—prostate cancer	3.63e-05	0.000183	CcSEcCtD
Atomoxetine—Dyspepsia—Epirubicin—prostate cancer	3.63e-05	0.000183	CcSEcCtD
Atomoxetine—Diarrhoea—Prednisone—prostate cancer	3.61e-05	0.000182	CcSEcCtD
Atomoxetine—Decreased appetite—Epirubicin—prostate cancer	3.58e-05	0.000181	CcSEcCtD
Atomoxetine—Phenoxybenzamine—CYP3A4—prostate cancer	3.57e-05	0.00693	CrCbGaD
Atomoxetine—Gastrointestinal disorder—Epirubicin—prostate cancer	3.56e-05	0.000179	CcSEcCtD
Atomoxetine—Fatigue—Epirubicin—prostate cancer	3.55e-05	0.000179	CcSEcCtD
Atomoxetine—Pain—Epirubicin—prostate cancer	3.52e-05	0.000178	CcSEcCtD
Atomoxetine—Constipation—Epirubicin—prostate cancer	3.52e-05	0.000178	CcSEcCtD
Atomoxetine—Propranolol—CYP3A4—prostate cancer	3.52e-05	0.00683	CrCbGaD
Atomoxetine—Nausea—Capecitabine—prostate cancer	3.51e-05	0.000177	CcSEcCtD
Atomoxetine—Dizziness—Prednisone—prostate cancer	3.48e-05	0.000176	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Doxorubicin—prostate cancer	3.47e-05	0.000175	CcSEcCtD
Atomoxetine—Insomnia—Doxorubicin—prostate cancer	3.45e-05	0.000174	CcSEcCtD
Atomoxetine—Paraesthesia—Doxorubicin—prostate cancer	3.42e-05	0.000173	CcSEcCtD
Atomoxetine—Feeling abnormal—Epirubicin—prostate cancer	3.4e-05	0.000171	CcSEcCtD
Atomoxetine—Somnolence—Doxorubicin—prostate cancer	3.39e-05	0.000171	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Epirubicin—prostate cancer	3.37e-05	0.00017	CcSEcCtD
Atomoxetine—Dyspepsia—Doxorubicin—prostate cancer	3.36e-05	0.000169	CcSEcCtD
Atomoxetine—Vomiting—Prednisone—prostate cancer	3.35e-05	0.000169	CcSEcCtD
Atomoxetine—Rash—Prednisone—prostate cancer	3.32e-05	0.000167	CcSEcCtD
Atomoxetine—Dermatitis—Prednisone—prostate cancer	3.32e-05	0.000167	CcSEcCtD
Atomoxetine—Decreased appetite—Doxorubicin—prostate cancer	3.31e-05	0.000167	CcSEcCtD
Atomoxetine—Headache—Prednisone—prostate cancer	3.3e-05	0.000166	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Doxorubicin—prostate cancer	3.29e-05	0.000166	CcSEcCtD
Atomoxetine—Fatigue—Doxorubicin—prostate cancer	3.29e-05	0.000166	CcSEcCtD
Atomoxetine—Urticaria—Epirubicin—prostate cancer	3.27e-05	0.000165	CcSEcCtD
Atomoxetine—Constipation—Doxorubicin—prostate cancer	3.26e-05	0.000164	CcSEcCtD
Atomoxetine—Pain—Doxorubicin—prostate cancer	3.26e-05	0.000164	CcSEcCtD
Atomoxetine—Abdominal pain—Epirubicin—prostate cancer	3.26e-05	0.000164	CcSEcCtD
Atomoxetine—Body temperature increased—Epirubicin—prostate cancer	3.26e-05	0.000164	CcSEcCtD
Atomoxetine—Nortriptyline—CYP3A4—prostate cancer	3.23e-05	0.00628	CrCbGaD
Atomoxetine—Feeling abnormal—Doxorubicin—prostate cancer	3.14e-05	0.000158	CcSEcCtD
Atomoxetine—Nausea—Prednisone—prostate cancer	3.13e-05	0.000158	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Doxorubicin—prostate cancer	3.12e-05	0.000157	CcSEcCtD
Atomoxetine—Urticaria—Doxorubicin—prostate cancer	3.03e-05	0.000153	CcSEcCtD
Atomoxetine—Abdominal pain—Doxorubicin—prostate cancer	3.01e-05	0.000152	CcSEcCtD
Atomoxetine—Body temperature increased—Doxorubicin—prostate cancer	3.01e-05	0.000152	CcSEcCtD
Atomoxetine—Asthenia—Epirubicin—prostate cancer	2.96e-05	0.000149	CcSEcCtD
Atomoxetine—Pruritus—Epirubicin—prostate cancer	2.92e-05	0.000147	CcSEcCtD
Atomoxetine—Methadone—CYP3A4—prostate cancer	2.89e-05	0.00561	CrCbGaD
Atomoxetine—Orphenadrine—CYP3A4—prostate cancer	2.83e-05	0.0055	CrCbGaD
Atomoxetine—Diarrhoea—Epirubicin—prostate cancer	2.82e-05	0.000142	CcSEcCtD
Atomoxetine—Asthenia—Doxorubicin—prostate cancer	2.74e-05	0.000138	CcSEcCtD
Atomoxetine—Dizziness—Epirubicin—prostate cancer	2.73e-05	0.000137	CcSEcCtD
Atomoxetine—Pruritus—Doxorubicin—prostate cancer	2.7e-05	0.000136	CcSEcCtD
Atomoxetine—Desipramine—CYP3A4—prostate cancer	2.66e-05	0.00517	CrCbGaD
Atomoxetine—Vomiting—Epirubicin—prostate cancer	2.62e-05	0.000132	CcSEcCtD
Atomoxetine—Diarrhoea—Doxorubicin—prostate cancer	2.61e-05	0.000132	CcSEcCtD
Atomoxetine—Rash—Epirubicin—prostate cancer	2.6e-05	0.000131	CcSEcCtD
Atomoxetine—Dermatitis—Epirubicin—prostate cancer	2.6e-05	0.000131	CcSEcCtD
Atomoxetine—Headache—Epirubicin—prostate cancer	2.58e-05	0.00013	CcSEcCtD
Atomoxetine—Dizziness—Doxorubicin—prostate cancer	2.52e-05	0.000127	CcSEcCtD
Atomoxetine—Nausea—Epirubicin—prostate cancer	2.45e-05	0.000123	CcSEcCtD
Atomoxetine—Vomiting—Doxorubicin—prostate cancer	2.42e-05	0.000122	CcSEcCtD
Atomoxetine—Rash—Doxorubicin—prostate cancer	2.4e-05	0.000121	CcSEcCtD
Atomoxetine—Dermatitis—Doxorubicin—prostate cancer	2.4e-05	0.000121	CcSEcCtD
Atomoxetine—Headache—Doxorubicin—prostate cancer	2.39e-05	0.00012	CcSEcCtD
Atomoxetine—Nausea—Doxorubicin—prostate cancer	2.26e-05	0.000114	CcSEcCtD
Atomoxetine—HTR6—Signaling Pathways—CDKN1B—prostate cancer	3.58e-06	3.44e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CYP19A1—prostate cancer	3.58e-06	3.44e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CXCL8—prostate cancer	3.57e-06	3.43e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CDKN1B—prostate cancer	3.56e-06	3.42e-05	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—AKT1—prostate cancer	3.55e-06	3.41e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ITPR1—prostate cancer	3.54e-06	3.4e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—MED12—prostate cancer	3.53e-06	3.39e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—LEP—prostate cancer	3.53e-06	3.39e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—GSK3B—prostate cancer	3.52e-06	3.38e-05	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—AKT1—prostate cancer	3.52e-06	3.38e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CASP3—prostate cancer	3.51e-06	3.37e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IL2—prostate cancer	3.51e-06	3.37e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GNG5—prostate cancer	3.5e-06	3.37e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CAV1—prostate cancer	3.5e-06	3.36e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—IL6—prostate cancer	3.49e-06	3.35e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CASP3—prostate cancer	3.49e-06	3.35e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—EP300—prostate cancer	3.48e-06	3.35e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CDKN1B—prostate cancer	3.48e-06	3.34e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IL2—prostate cancer	3.48e-06	3.34e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—INS—prostate cancer	3.47e-06	3.34e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—IL6—prostate cancer	3.46e-06	3.33e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—KDR—prostate cancer	3.46e-06	3.32e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—RXRA—prostate cancer	3.45e-06	3.32e-05	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—AKT1—prostate cancer	3.45e-06	3.31e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CCND1—prostate cancer	3.42e-06	3.28e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CASP3—prostate cancer	3.41e-06	3.28e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IL2—prostate cancer	3.41e-06	3.27e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CREBBP—prostate cancer	3.4e-06	3.27e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CCND1—prostate cancer	3.39e-06	3.26e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—IL6—prostate cancer	3.39e-06	3.26e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CTNNB1—prostate cancer	3.39e-06	3.25e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—NCOA3—prostate cancer	3.38e-06	3.24e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—ESR1—prostate cancer	3.37e-06	3.24e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IGF1—prostate cancer	3.36e-06	3.23e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CTNNB1—prostate cancer	3.36e-06	3.23e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—TYMS—prostate cancer	3.35e-06	3.21e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—EGFR—prostate cancer	3.34e-06	3.21e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—COMT—prostate cancer	3.33e-06	3.2e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CCND1—prostate cancer	3.32e-06	3.19e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MMP9—prostate cancer	3.32e-06	3.19e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GSTP1—prostate cancer	3.31e-06	3.18e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GSTM1—prostate cancer	3.31e-06	3.18e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CDKN1A—prostate cancer	3.31e-06	3.18e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PTEN—prostate cancer	3.3e-06	3.17e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MMP9—prostate cancer	3.29e-06	3.16e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—BAD—prostate cancer	3.29e-06	3.16e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CTNNB1—prostate cancer	3.29e-06	3.16e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CDKN1A—prostate cancer	3.28e-06	3.15e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PTEN—prostate cancer	3.28e-06	3.15e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ITPR1—prostate cancer	3.26e-06	3.13e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MAP2K1—prostate cancer	3.25e-06	3.12e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—LPL—prostate cancer	3.25e-06	3.12e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PIK3CD—prostate cancer	3.23e-06	3.1e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MMP9—prostate cancer	3.23e-06	3.1e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—HPGDS—prostate cancer	3.22e-06	3.09e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—AKT1—prostate cancer	3.22e-06	3.09e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CDKN1A—prostate cancer	3.21e-06	3.09e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PTEN—prostate cancer	3.21e-06	3.08e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYP2C19—prostate cancer	3.2e-06	3.07e-05	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—PIK3CA—prostate cancer	3.2e-06	3.07e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—AKT1—prostate cancer	3.2e-06	3.07e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—SERPINE1—prostate cancer	3.19e-06	3.07e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PIK3CG—prostate cancer	3.19e-06	3.06e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—APC—prostate cancer	3.19e-06	3.06e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—KRAS—prostate cancer	3.16e-06	3.03e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—EGF—prostate cancer	3.15e-06	3.03e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IRS1—prostate cancer	3.15e-06	3.03e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—EP300—prostate cancer	3.15e-06	3.02e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CYP1A1—prostate cancer	3.14e-06	3.01e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—AKT1—prostate cancer	3.13e-06	3e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ACHE—prostate cancer	3.12e-06	3e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GSTT1—prostate cancer	3.12e-06	3e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—EP300—prostate cancer	3.12e-06	3e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ERCC2—prostate cancer	3.11e-06	2.99e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—FGF2—prostate cancer	3.09e-06	2.97e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYP2A6—prostate cancer	3.09e-06	2.97e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—TYMS—prostate cancer	3.08e-06	2.96e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—SRC—prostate cancer	3.06e-06	2.94e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—GSK3B—prostate cancer	3.06e-06	2.94e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—EP300—prostate cancer	3.06e-06	2.94e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—NOS3—prostate cancer	3.05e-06	2.93e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GSTM1—prostate cancer	3.04e-06	2.92e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—SRC—prostate cancer	3.04e-06	2.92e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—INS—prostate cancer	3.02e-06	2.9e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—AKR1C3—prostate cancer	3e-06	2.88e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PRKACB—prostate cancer	2.99e-06	2.87e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—LPL—prostate cancer	2.99e-06	2.87e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—VEGFA—prostate cancer	2.98e-06	2.86e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—SRC—prostate cancer	2.97e-06	2.86e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—JAK2—prostate cancer	2.96e-06	2.84e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—VEGFA—prostate cancer	2.96e-06	2.84e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYP17A1—prostate cancer	2.96e-06	2.84e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CREBBP—prostate cancer	2.96e-06	2.84e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—STAT3—prostate cancer	2.95e-06	2.83e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—STAT3—prostate cancer	2.93e-06	2.81e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—MTHFR—prostate cancer	2.92e-06	2.81e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IGF1—prostate cancer	2.92e-06	2.8e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—EGFR—prostate cancer	2.9e-06	2.79e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—PIK3CA—prostate cancer	2.9e-06	2.79e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—VEGFA—prostate cancer	2.9e-06	2.78e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MDM2—prostate cancer	2.89e-06	2.78e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CYP1A1—prostate cancer	2.89e-06	2.77e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PPARA—prostate cancer	2.87e-06	2.76e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—STAT3—prostate cancer	2.87e-06	2.75e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ERCC2—prostate cancer	2.86e-06	2.75e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—ERBB2—prostate cancer	2.85e-06	2.74e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MAP2K1—prostate cancer	2.82e-06	2.71e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—NCOA2—prostate cancer	2.82e-06	2.71e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PIK3CB—prostate cancer	2.81e-06	2.7e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PIK3CD—prostate cancer	2.8e-06	2.69e-05	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—PIK3CA—prostate cancer	2.78e-06	2.67e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—SERPINE1—prostate cancer	2.77e-06	2.66e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—KRAS—prostate cancer	2.74e-06	2.63e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MYC—prostate cancer	2.74e-06	2.63e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TGFB1—prostate cancer	2.74e-06	2.63e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MYC—prostate cancer	2.72e-06	2.61e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TGFB1—prostate cancer	2.72e-06	2.61e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CXCL8—prostate cancer	2.7e-06	2.6e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CAV1—prostate cancer	2.7e-06	2.59e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—MTHFR—prostate cancer	2.69e-06	2.58e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—SLC5A5—prostate cancer	2.69e-06	2.58e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—FGF2—prostate cancer	2.68e-06	2.58e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—EGFR—prostate cancer	2.68e-06	2.58e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MYC—prostate cancer	2.66e-06	2.56e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—EGFR—prostate cancer	2.66e-06	2.56e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TGFB1—prostate cancer	2.66e-06	2.55e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NOS3—prostate cancer	2.65e-06	2.54e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CDKN1B—prostate cancer	2.64e-06	2.53e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PPARA—prostate cancer	2.64e-06	2.53e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYP2E1—prostate cancer	2.63e-06	2.52e-05	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—AKT1—prostate cancer	2.61e-06	2.51e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—EGFR—prostate cancer	2.61e-06	2.5e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—NQO1—prostate cancer	2.6e-06	2.49e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CASP3—prostate cancer	2.59e-06	2.48e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IL2—prostate cancer	2.58e-06	2.48e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	2.58e-06	2.47e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—JAK2—prostate cancer	2.57e-06	2.47e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—IL6—prostate cancer	2.57e-06	2.47e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—TH—prostate cancer	2.56e-06	2.46e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—KRAS—prostate cancer	2.53e-06	2.43e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—PIK3CA—prostate cancer	2.52e-06	2.42e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CCND1—prostate cancer	2.52e-06	2.42e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—KRAS—prostate cancer	2.51e-06	2.42e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MDM2—prostate cancer	2.51e-06	2.41e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CTNNB1—prostate cancer	2.49e-06	2.39e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYP1B1—prostate cancer	2.49e-06	2.39e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CAV1—prostate cancer	2.48e-06	2.38e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—ERBB2—prostate cancer	2.47e-06	2.38e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—KRAS—prostate cancer	2.46e-06	2.36e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PIK3CG—prostate cancer	2.46e-06	2.36e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MMP9—prostate cancer	2.44e-06	2.35e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PIK3CB—prostate cancer	2.44e-06	2.35e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CDKN1A—prostate cancer	2.44e-06	2.34e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PTEN—prostate cancer	2.43e-06	2.33e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GGT1—prostate cancer	2.41e-06	2.32e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—NCOA1—prostate cancer	2.37e-06	2.28e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—AKT1—prostate cancer	2.37e-06	2.28e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CXCL8—prostate cancer	2.35e-06	2.25e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYP19A1—prostate cancer	2.34e-06	2.25e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PIK3CA—prostate cancer	2.33e-06	2.24e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—INS—prostate cancer	2.33e-06	2.23e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—EP300—prostate cancer	2.32e-06	2.23e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PIK3CA—prostate cancer	2.31e-06	2.22e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CDKN1B—prostate cancer	2.29e-06	2.2e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CREBBP—prostate cancer	2.28e-06	2.19e-05	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—AKT1—prostate cancer	2.27e-06	2.18e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PIK3CA—prostate cancer	2.26e-06	2.17e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PIK3CG—prostate cancer	2.26e-06	2.17e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—RXRA—prostate cancer	2.26e-06	2.17e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—SRC—prostate cancer	2.25e-06	2.16e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TP53—prostate cancer	2.25e-06	2.16e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CASP3—prostate cancer	2.25e-06	2.16e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IL2—prostate cancer	2.24e-06	2.15e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TP53—prostate cancer	2.24e-06	2.15e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—IL6—prostate cancer	2.23e-06	2.14e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—VEGFA—prostate cancer	2.2e-06	2.11e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TP53—prostate cancer	2.19e-06	2.1e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CCND1—prostate cancer	2.19e-06	2.1e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—COMT—prostate cancer	2.18e-06	2.09e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—STAT3—prostate cancer	2.17e-06	2.09e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CTNNB1—prostate cancer	2.17e-06	2.08e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GSTP1—prostate cancer	2.17e-06	2.08e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PIK3CD—prostate cancer	2.16e-06	2.07e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—INS—prostate cancer	2.14e-06	2.05e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ITPR1—prostate cancer	2.13e-06	2.05e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MMP9—prostate cancer	2.12e-06	2.04e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CDKN1A—prostate cancer	2.12e-06	2.03e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PTEN—prostate cancer	2.11e-06	2.03e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CREBBP—prostate cancer	2.1e-06	2.01e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IL6—prostate cancer	2.06e-06	1.98e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—AKT1—prostate cancer	2.06e-06	1.98e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IL6—prostate cancer	2.05e-06	1.96e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—NOS3—prostate cancer	2.04e-06	1.96e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MYC—prostate cancer	2.02e-06	1.94e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TGFB1—prostate cancer	2.01e-06	1.93e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—TYMS—prostate cancer	2.01e-06	1.93e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—EP300—prostate cancer	2.01e-06	1.93e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IL6—prostate cancer	2e-06	1.92e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GSTM1—prostate cancer	1.99e-06	1.91e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PIK3CD—prostate cancer	1.99e-06	1.91e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—EGFR—prostate cancer	1.98e-06	1.9e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—SRC—prostate cancer	1.96e-06	1.88e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—LPL—prostate cancer	1.95e-06	1.88e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—VEGFA—prostate cancer	1.91e-06	1.83e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—AKT1—prostate cancer	1.9e-06	1.83e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—AKT1—prostate cancer	1.89e-06	1.81e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—STAT3—prostate cancer	1.89e-06	1.81e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYP1A1—prostate cancer	1.89e-06	1.81e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PIK3CB—prostate cancer	1.88e-06	1.81e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—NOS3—prostate cancer	1.88e-06	1.8e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ERCC2—prostate cancer	1.87e-06	1.8e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—KRAS—prostate cancer	1.87e-06	1.79e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PTGS2—prostate cancer	1.87e-06	1.79e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—AKT1—prostate cancer	1.85e-06	1.77e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—MTHFR—prostate cancer	1.76e-06	1.69e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MYC—prostate cancer	1.75e-06	1.68e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TGFB1—prostate cancer	1.75e-06	1.68e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PIK3CB—prostate cancer	1.73e-06	1.66e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PPARA—prostate cancer	1.73e-06	1.66e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PTGS2—prostate cancer	1.72e-06	1.65e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—EGFR—prostate cancer	1.72e-06	1.65e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PIK3CA—prostate cancer	1.71e-06	1.65e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TP53—prostate cancer	1.66e-06	1.59e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PTEN—prostate cancer	1.63e-06	1.56e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CAV1—prostate cancer	1.62e-06	1.56e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—KRAS—prostate cancer	1.62e-06	1.56e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—EP300—prostate cancer	1.55e-06	1.49e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IL6—prostate cancer	1.52e-06	1.46e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PTEN—prostate cancer	1.5e-06	1.44e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PIK3CA—prostate cancer	1.49e-06	1.43e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PIK3CG—prostate cancer	1.48e-06	1.42e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TP53—prostate cancer	1.44e-06	1.38e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—EP300—prostate cancer	1.43e-06	1.37e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—AKT1—prostate cancer	1.4e-06	1.35e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—INS—prostate cancer	1.4e-06	1.34e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CREBBP—prostate cancer	1.37e-06	1.32e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IL6—prostate cancer	1.32e-06	1.27e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PIK3CD—prostate cancer	1.3e-06	1.25e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—NOS3—prostate cancer	1.23e-06	1.18e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—AKT1—prostate cancer	1.22e-06	1.17e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PIK3CA—prostate cancer	1.15e-06	1.1e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PIK3CB—prostate cancer	1.13e-06	1.09e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PTGS2—prostate cancer	1.12e-06	1.08e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PIK3CA—prostate cancer	1.06e-06	1.01e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PTEN—prostate cancer	9.78e-07	9.4e-06	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—AKT1—prostate cancer	9.38e-07	9e-06	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—EP300—prostate cancer	9.33e-07	8.96e-06	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—AKT1—prostate cancer	8.62e-07	8.28e-06	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PIK3CA—prostate cancer	6.9e-07	6.63e-06	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—AKT1—prostate cancer	5.64e-07	5.41e-06	CbGpPWpGaD
